β-Adrenoceptor modulation in chronic obstructive pulmonary disease: present and future perspectives. (Q38152743)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127222%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

β-Adrenoceptor modulation in chronic obstructive pulmonary disease: present and future perspectives (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127222%20AND%20SRC:MED&resulttype=core&format=json

chronic obstructive pulmonary disease

27 February 2020

main subject

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127222%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

Maria Gabriella Matera

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127222%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Mario Cazzola

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127222%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

publication date

1 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127222%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127222%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

73

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127222%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127222%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

1653-1663

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127222%20AND%20SRC:MED&resulttype=core&format=json

β-blockade: benefits beyond blood pressure reduction?

27 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Pharmacological modulation of beta-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Pharmacology and therapeutics of bronchodilators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

β2-agonist therapy in lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Novel cAMP signalling paradigms: therapeutic implications for airway disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Therapeutic potential of β-arrestin- and G protein-biased agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

beta-Arrestin: a protein that regulates beta-adrenergic receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Desensitization, internalization, and signaling functions of beta-arrestins demonstrated by RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Reflex regulation of airway smooth muscle tone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Neurohumoral activation as a link to systemic manifestations of chronic lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Reduced baroreceptor sensitivity in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Marked sympathetic activation in patients with chronic respiratory failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Post-exercise heart rate recovery and mortality in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Long acting beta(2) agonists and theophylline in stable chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Short-term effects of inhaled salbutamol on autonomic cardiovascular control in healthy subjects: a placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Heart-rate variability effects of beta-adrenoceptor agonists (xamoterol, prenalterol, and salbutamol) assessed nonlinearly with scatterplots and sequence methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Evaluation of the effect on heart rate variability of a beta2-adrenoceptor agonist and antagonist using non-linear scatterplot and sequence methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

β(2) -adrenoceptor agonists: current and future direction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Cardiovascular events in patients with COPD: TORCH study results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Beta-agonist intrinsic efficacy: measurement and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Bronchodilator responsiveness in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Should acute treatment with inhaled beta agonists be withheld from patients with dyspnea who may have heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Heart failure and COPD: partners in crime?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Asthma, beta-agonists, and development of congestive heart failure: results of the ABCHF study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Are beta2-agonists responsible for increased mortality in heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Cardiac safety of formoterol 12 microg twice daily in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Expert consensus document on beta-adrenergic receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Cardio-selective and non-selective beta-blockers in chronic obstructive pulmonary disease: effects on bronchodilator response and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Beta-blockers are safe in patients with chronic obstructive pulmonary disease, but only with caution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Use of Cardioselective ß-Blockers in Patients with Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized, Placebo-controlled, Blinded Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Beta-blocker use and COPD mortality: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Treatment of COPD: moving beyond the lungs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Investigating the adverse respiratory effects of β-blocker treatment: six years of prospective longitudinal data in a cohort with cardiac disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Association between β-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Changes in beta 2-adrenoceptor and other signaling proteins produced by chronic administration of 'beta-blockers' in a murine asthma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

The effects of acute and chronic nadolol treatment on β2AR signaling in HEK293 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Role of alveolar β2-adrenergic receptors on lung fluid clearance and exercise ventilation in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

beta-Adrenoceptor inverse agonists in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Embracing emerging paradigms of G protein-coupled receptor agonism and signaling to address airway smooth muscle pathobiology in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Tolerance to bronchodilating effects of salmeterol in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Exacerbations of Bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Mucus in chronic airway diseases: sorting out the sticky details

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

The lung health study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. The Lung Health Study Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Resting heart rate is a predictor of mortality in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

2007 Guidelines for the Management of Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Structure of β-Adrenergic Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Bronchodilator Therapy in Acute Decompensated Heart Failure Patients Without a History of Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Clinical and inflammatory determinants of bronchial hyperresponsiveness in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0120-5

Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure

21 January 2018

1 reference

12 December 2020

Chronic obstructive pulmonary disease: a slowly progressive cardiovascular disease masked by its pulmonary effects?

1 reference

12 December 2020

Sympathetic overactivity and cardiovascular disease in patients with chronic obstructive pulmonary disease (COPD).

1 reference

12 December 2020

Beta-adrenergic and muscarinic cholinergic receptor densities in the human sinoatrial node: identification of a high beta 2-adrenergic receptor density

1 reference

12 December 2020

Beta-agonists for patients with chronic obstructive pulmonary disease and heart disease?

1 reference

12 December 2020

Beta 1- and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure

1 reference

12 December 2020

Paradoxical pharmacology: turning our pharmacological models upside down

1 reference

12 December 2020

Cardioselective beta-blockers for chronic obstructive pulmonary disease

1 reference

12 December 2020

Respiratory illness, beta-agonists, and risk of idiopathic dilated cardiomyopathy. The Washington, DC, Dilated Cardiomyopathy Study

1 reference

12 December 2020

Association between chronic heart failure and inhaled beta-2-adrenoceptor agonists

1 reference

12 December 2020

Acute effects of beta 1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure

1 reference

12 December 2020

Increased sympathetic nerve activity in pulmonary artery hypertension

1 reference

12 December 2020

Biases in the observational study of beta blockers in COPD.

1 reference

12 December 2020

Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study

1 reference

12 December 2020

Should long-acting beta 2-agonists be considered an alternative first choice option for the treatment of stable COPD?

1 reference

12 December 2020

Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia

1 reference

12 December 2020

Decreased heart rate variability in patients with chronic obstructive pulmonary disease

1 reference

12 December 2020

Cardiac output during exercise in patients with COPD

1 reference

12 December 2020

The beta-adrenoceptor

1 reference

12 December 2020

Inotropic and sympathetic responses to the intracoronary infusion of a beta2-receptor agonist: a human in vivo study

1 reference

12 December 2020

Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction

1 reference

12 December 2020

Evidence of tachyphylaxis associated with salmeterol treatment of chronic obstructive pulmonary disease patients

1 reference

12 December 2020

Randomized placebo-controlled trial to evaluate chronic dosing effects of propranolol in asthma

1 reference

12 December 2020

β-Adrenoceptor blockers and pulmonary function in the general population: the Rotterdam Study

1 reference

12 December 2020

β-Blocker use and incidence of chronic obstructive pulmonary disease exacerbations

1 reference

12 December 2020

Neutrophils, airway hyperresponsiveness and COPD: true, true and related?

1 reference

12 December 2020

Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD

1 reference

12 December 2020

Treatment with beta blockers in people with COPD

1 reference

12 December 2020

10.1007/S40265-013-0120-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127222%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

27 February 2020

1017320793

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24127222%20AND%20SRC:MED&resulttype=core&format=json